Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Safest Dividend Stocks to Buy Right Now.
On May 21, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the company, together with its subsidiary Kite, will present over 25 abstracts at the 2026 ASCO Annual Meeting (May 29 – June 2) and the EHA Congress (June 11 – 14), showcasing progress in cancer therapies. Key ASCO presentations include new late-stage Phase 3 analyses for Trodelvy in first-line metastatic triple-negative breast cancer, focusing on long-term progression-free survival. For the first time, Kite will also introduce manufacturing consistency data for anito-cel, an investigational CAR T-cell therapy for multiple myeloma. In addition, EHA updates will showcase the results regarding the durability and safety of an enhanced CAR T-cell therapy called KITE-753 that targets relapsed/refractory B-cell lymphoma.
In a recent development, Gilead Sciences, Inc. (NASDAQ:GILD) announced new Phase 3 interim data showing Livdelzi achieved high and sustained normalization of a key liver marker (ALP) in primary biliary cholangitis patients. According to the results, the drug was well-tolerated over two years of treatment.
Founded in 1987 and headquartered in California, Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It has paid uninterrupted quarterly dividends for ten consecutive years.
While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: Leopold Aschenbrenner’s Portfolio: 10 Best Stocks to Buy and Steve Cohen Stock Portfolio: Top 10 Stock Picks
Disclosure: None. Follow Insider Monkey on Google News.
